Using cutting-edge breath sampling, scientists have achieved a breakthrough in diagnosing lower respiratory tract infections with an in vitro assay that could transform patient care in ICUs worldwide.
Standard bioassays often fall short when evaluating T cell engagers due to their diverse mechanisms of actions (MOAs) and functional complexity. To generate meaningful preclinical data, ...
The MarketWatch News Department was not involved in the creation of this content. BOSTON, Jan. 8, 2026 /PRNewswire/ -- Perceptive Discovery, the preclinical and translational services division of ...
Motivated by the latest drug development regulatory guidance, such as the US Food and Drug Administration Modernization Act 2.0, academic and biopharmaceutical industry professionals are increasingly ...
Market OutlookThe global in vitro toxicity testing market is expected to expand at a compound annual growth rate of around 10% during the forecast period, reflecting the increasing need for safer, ...
Angiogenesis plays a critical role in a wide range of biological processes, including wound healing, reproduction, and cancer. Scientists engaged in angiogenesis drug development research seek ways to ...
Currently, only 10% of the drugs that enter Phase I receive marketing approval from the U.S. Food and Drug Administration (FDA), with unmanageable toxicity accounting for approximately 30% of the ...
ELRIG, a not-for-profit, volunteer-led organization dedicated to the global drug discovery community, today announced the keynote speakers for Advances in Cell-based Screening 2026, taking place at ...
This webinar examines practical approaches to strengthening lateral flow assay performance, with a focus on optimized sample ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results